Related Experiment Video
Updated: Nov 13, 2025
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Increased expression of IFI16 predicts adverse prognosis in multiple myeloma
Wenhui Huang1,2,3, Tingting Qian1,2,3, Zeyong Huang1,2,3
1Department of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Abstract:
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells and does not have sufficient prognostic indicators. Interferon gamma inducible protein 16 (IFI16) plays a crucial role in B-cell differentiation. Several studies have shown that IFI16 predicted prognosis in many cancers. However, the relationship between MM prognosis and IFI16 expression has not been studied. In our study, we analyzed the prognostic role of IFI16 expression and explored the possible mechanism in MM progression by using 4498 myeloma patients and 52 healthy donors from 13 independent gene expression omnibus (GEO) datasets. The IFI16 expression increased with myeloma progression, ISS stage, 1q21 amplification, and relapse (all P < 0.01). MM patients with higher IFI16 expression had shorter survival in six datasets (all P < 0.05). Furthermore, multivariate analysis indicated that enhanced IFI16 expression was an independent poor prognostic factor for EFS and OS (P = 0.007, 0.009, respectively). And PPI, GO, KEGG, and GSEA also confirmed that IFI16 promoted MM progression by participating in tumor-related pathways. In conclusion, our study confirmed that IFI16 was a poor prognostic biomarker in MM.
Insights
Interferon gamma inducible protein 16 (IFI16) is a poor prognostic biomarker in multiple myeloma (MM). Higher IFI16 expression correlates with disease progression and shorter survival, indicating its role in MM advancement.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Multiple myeloma (MM) lacks sufficient prognostic indicators for plasma cell malignancies.
- Interferon gamma inducible protein 16 (IFI16) is vital in B-cell differentiation and shows prognostic value in various cancers.
- The prognostic significance of IFI16 in MM remains uninvestigated.
Purpose of the Study:
- To analyze the prognostic role of IFI16 expression in MM.
- To explore the potential mechanisms of IFI16 in MM progression.
Main Methods:
- Utilized 13 independent Gene Expression Omnibus (GEO) datasets comprising 4498 MM patients and 52 healthy donors.
- Analyzed IFI16 expression in relation to MM progression, ISS stage, 1q21 amplification, and relapse.
- Performed multivariate analysis for event-free survival (EFS) and overall survival (OS).
- Employed pathway analysis including Protein-Protein Interaction (PPI), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA).
Main Results:
- IFI16 expression significantly increased with MM progression, advanced ISS stage, 1q21 amplification, and relapse (P < 0.01).
- Higher IFI16 expression was associated with shorter survival in MM patients across six datasets (P < 0.05).
- Multivariate analysis identified elevated IFI16 expression as an independent predictor of poor EFS and OS (P = 0.007, 0.009).
- Pathway analyses confirmed IFI16's role in promoting MM progression via tumor-related pathways.
Conclusions:
- IFI16 serves as a valuable prognostic biomarker in multiple myeloma.
- Elevated IFI16 expression is indicative of a poorer prognosis and contributes to MM progression.
More Related Videos
09:01Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
